Scientific Advisory Board (SAB)

Peptomyc S.L. benefits from the expertise of a strong Scientific Advisory Board (SAB) comprising the following internationally renowned thought leaders in oncology:



Josep Tabernero

josep-tabernero

Head of the Medical Oncology Department of the Vall d’Hebron University Hospital; Director of the Vall d’Hebron Institute of Oncology, Barcelona, Spain.

 

Dr. Tabernero holds both a MD and PhD degree from the Universitat Autónoma de Barcelona, Spain. He coordinates programs in translational research and pharmacodynamics Phase I studies with molecular targeted therapies. He is particularly focused on Phase I and II pharmacodynamics endpoint studies with novel agents that target membrane receptors, such as the EGFR family and IGF-1R, the PI3K and ERK signaling pathways, as well as downstream cytoplasmic and intra-nucleus effectors such as Mdm2/p53 and Aurora kinase.

His research group aims at developing new molecular therapies that target specific oncoproteins and genetic identity of different tumors, with the purpose of achieving precision medicine. One of the main objectives of the group is also the identification of new predictive markers of response to diverse treatments as well as markers of primary resistance (de novo) and secondary treatment.

Josep has recently been elected to serve as President of the European Society for Medical Oncology (ESMO) 2018-2019, and is also member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He is active member of various Editorial Boards, including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology.

back to top


Josep Baselga

josep-baselga

Physician-in-Chief, the Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA

 

José Baselga is the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weil Cornell Medical College. His long standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 350 peer-reviewed publications to date. Prior to MSK, Dr. Baselga was the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He also was the Chairman of Medical Oncology and Founding Director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga is the President of the American Association of Cancer Research (AACR), a past President of the European Society for Medical Oncology, and a past member of the Board of Directors for the American Society of Clinical Oncology and AACR. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and a Fellow of the AACR Academy. He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal Cancer Discovery.

back to top


Roger Stupp

Roger-Stupp

Professor and Chairman, Department of Oncology
Director, University Hospital Cancer Center
University of Zurich, Zurich/Switzerland
President, European Organization for Research and Treatment of Cancer (EORTC)

Roger Stupp trained in Internal Medicine, Oncology/Hematology in Switzerland and at the University of Chicago. He worked over 17 years as a physician and researcher at the University of Lausanne, before being appointed in 2013 as the Director of the Department of Oncology and Cancer Center at the University Hospital in Zurich, Switzerland. He has been a member of the European Organization for Research and Treatment of Cancer (EORTC) since 1994, and serves as the President of the organization since 2012. Dr. Stupp’s research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. He is involved in bringing innovative and multimodal treatments to the clinic. Roger Stupp has been the principal investigator for large multimodality clinical trials in brain tumors and non-small cell lung cancer.

Dr. Stupp is section editor for the European Journal of Cancer. He serves in scientific or educational committees of the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO); he also acts as a consultant for several European and National funding agencies.

back to top


Enriqueta Felip

Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain

 

Enriqueta Felip is Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain. She is also Associate Professor at the Autonomous University of Barcelona (UAB). Enriqueta Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology.

Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Current research lines include the individualization of chemotherapy in early-stage disease, the use of pharmacogenomic approaches, the evaluation of new drugs, and the optimization of immunotherapy strategies.

She is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the National Lung Cancer Partnership. She is the coordinator of the lung cancer program of the European School of Oncology (ESO). Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

back to top